Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD
stevepb / Pixabay

Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD

Cynata Therapeutics, an Australian stem cell and regenerative medicine company, has announced positive results from a Phase 1 clinical trial of CYP-001, the CymerusTM mesenchymal stem cell product candidate. The study…

Continue Reading Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD
Centering Patients in Medical Research Means Giving Them Access to Their Results
geralt / Pixabay

Centering Patients in Medical Research Means Giving Them Access to Their Results

According to a story from statnews.com, Dr. Julia Brody, who heads the Silent Spring Institute located in Newton, Massachusetts, says that her laboratory has always allowed patients and study participants…

Continue Reading Centering Patients in Medical Research Means Giving Them Access to Their Results
Preliminary Results of Gene Editing Experiment Suggest Potential for Treating Hunter Syndrome
lisichik / Pixabay

Preliminary Results of Gene Editing Experiment Suggest Potential for Treating Hunter Syndrome

According to a story from the Santa Cruz Sentinel, the earliest results from a critical gene editing study could offer some encouragement for those hoping to treat rare genetic diseases…

Continue Reading Preliminary Results of Gene Editing Experiment Suggest Potential for Treating Hunter Syndrome

Data Looks Good For Synlogic’s Experimental Phenylketonuria Drug, And If You’re a Patient, You Can Get Involved

The biotechnology company Synlogic announced positive data from its most recent Phase 1/2a clinical trial of its experimental product SYNB1618. This trial did not test the therapeutic action of the…

Continue Reading Data Looks Good For Synlogic’s Experimental Phenylketonuria Drug, And If You’re a Patient, You Can Get Involved
The US FDA Has Approved Takhzyro for the Treatment of Hereditary Angioedema
qimono / Pixabay

The US FDA Has Approved Takhzyro for the Treatment of Hereditary Angioedema

The US Food and Drug Administration has approved a drug called TakhzyroTM (lanadelumab-flyo) for the treatment of hereditary angioedema. This approval was based on supporting evidence from several studies, including from…

Continue Reading The US FDA Has Approved Takhzyro for the Treatment of Hereditary Angioedema
Close Menu